The Lancet. Oncology 2014-02
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Abstract
Background
Patients with isolated locoregional recurrences (ILRR) of breast cancer have a high risk of distant metastasis and death from breast cancer. We aimed to establish whether adjuvant chemotherapy improves the outcome of such patients.
Methods
The CALOR trial was a pragmatic, open-label, randomised trial that accrued patients with histologically proven and completely excised ILRR after unilateral breast cancer who had undergone a mastectomy or lumpectomy with clear surgical margins. Eligible patients were enrolled from hospitals worldwide and were centrally randomised (1:1) to chemotherapy (type selected by the investigator; multidrug for at least four courses recommended) or no chemotherapy, using permuted blocks, and stratified by previous chemotherapy, oestrogen-receptor and progesterone-receptor status, and location of ILRR. Patients with oestrogen-receptor-positive ILRR received adjuvant endocrine therapy, radiation therapy was mandated for patients with microscopically involved surgical margins, and anti-HER2 therapy was optional. The primary endpoint was disease-free survival. All analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00074152.
Findings
From Aug 22, 2003, to Jan 31, 2010, 85 patients were randomly assigned to receive chemotherapy and 77 were assigned to no chemotherapy. At a median follow-up of 4·9 years (IQR 3·6-6 ·0), 24 (28%) patients had disease-free survival events in the chemotherapy group compared with 34 (44%) in the no chemotherapy group. 5-year disease-free survival was 69% (95% CI 56-79) with chemotherapy versus 57% (44-67) without chemotherapy (hazard ratio 0·59 [95% CI 0·35-0·99]; p=0·046). Adjuvant chemotherapy was significantly more effective for women with oestrogen-receptor-negative ILRR (pinteraction=0·046), but analyses of disease-free survival according to the oestrogen-receptor status of the primary tumour were not statistically significant (pinteraction=0·43). Of the 81 patients who received chemotherapy, 12 (15%) had serious adverse events. The most common adverse events were neutropenia, febrile neutropenia, and intestinal infection.
Interpretation
Adjuvant chemotherapy should be recommended for patients with completely resected ILRR of breast cancer, especially if the recurrence is oestrogen-receptor negative.
Funding
US Department of Health and Human Services, Swiss Group for Clinical Cancer Research (SAKK), Frontier Science and Technology Research Foundation, Australian and New Zealand Breast Cancer Trials Group, Swedish Cancer Society, Oncosuisse, Cancer Association of South Africa, Foundation for Clinical Research of Eastern Switzerland (OSKK), Grupo Español de Investigación en Cáncer de Mama (GEICAM), and the Dutch Breast Cancer Trialists' Group (BOOG).
Related Questions
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
I would start chemotherapy because of the triple-negative status of the metastasis. This is a patient who initially presented with hormone receptor-positive breast cancer and subsequently developed an isolated bone metastasis that was triple negative. The question of systemic therapy post-localized ...
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
The question does not provide the details of recurrence as to whether this is a locoregional breast recurrence, with or without lymph node or chest wall involvement. Ipsilateral or contralateral or second primary? Prior lumpectomy margins, prior type, and extent of radiation therapy? Time to recurre...
In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?
Endocrine therapy can be given simultaneously with RT without increasing toxicity or decreasing effectiveness, as shown in a randomized French-Swiss trial (Azria et al., PMID 20138810). Toxicities from chemotherapy may be greater and its effectiveness reduced (at least for high-risk patients) when g...
In which situations do you offer neoadjuvant chemotherapy for a nodal recurrence alone of ER/PR positive, HER2 negative breast cancer?
There is limited evidence to match this scenario on which to base the decision-making. On the one hand, this is a young woman who now has nodal disease. IF she had presented with this as her original diagnosis, the recommendation would have been for adjuvant chemotherapy followed by endocrine therap...
What adjuvant systemic therapy would you recommend for a woman s/p ALND for a nodal recurrence of ER-/HER2+ breast cancer 1 year after completing adjuvant therapy with paclitaxel/trastuzumab for her initial disease?
If the axillary nodes were already dissected, I would try TCHP followed by HP since she is pertuzumab naive and she had a DFI of >12 months from paclitaxel. If she had her nodes clipped for neoadjuvant TCHP, I would have switched to adjuvant TDM1 if she had residual disease in the axillary nodes.
Would you use OncoType Dx to guide adjuvant therapy recommendations in the context of locally recurrent, node-negative, ER+ breast cancer previously treated with endocrine therapy alone?
Assuming that 1.) the recurrence is in ipsilateral breast tissue post-radiation therapy, 2.) the patient is on adjuvant hormone therapy, and 3.) the pathologist concurs that this is not a new primary, we could approach this problem on multiple fronts.1.) Does the tumor harbor an ESR1 mutation? Altho...
What is optimal therapy for a 5 year delayed recurrence of uterine cancer, rendered NED by solitary pulmonary metastasis resection?
I favor “pseudoadjuvant” therapy with carboplatin + paclitaxel chemotherapy for 6 cycles. I make this recommendation in the absence of strong data to suggest an improvement in outcome with chemotherapy over observation vs. hormonal therapy. The optimal therapy for this patient with recurrent endomet...
How would you approach a post-menopausal women with recurrent ER/PR+, HER2- breast cancer only in the axillary lymph nodes?
This sounds so characteristic of a low-grade ER+ tumor in an elderly lady. I would only resect and confirm at resection the above-suspected pathology. Clearly given her age indolent behavior, local recurrence and low volume I would not torture this elderly lady with nothing more than an AI. The prob...
Would you offer systemic therapy before or after resection of an axillary-only recurrence of triple negative breast cancer?
I would most likely consider the neoadjuvant approach. - of course, few things to consider prior to making a decision. 1. How long was the duration between the previous completion of therapy for her first breast cancer? And was previous therapy complete, or rather was incomplete therapy was given? 2...
How would you treat recurrent unresectable skin nodules on the chest wall after mastectomy and axillary lymph node dissection?
I would consider systemic treatment first based on phenotype to see if that could make it resectable.I would favor that, as surgery followed by RT would offer a better outcome.As for as RT field is concerned, I would treat chest wall and regional nodal region routinely for the recurrent disease in c...
Do you recommend adjuvant chemotherapy for local relapse of invasive lobular carcinoma after surgical resection?
This one often depends on the nature of local relapse and whether relapse occurred on ET. The CALOR trial as flawed as it was suggested that chemotherapy helps in the "repeat adjuvant" setting, however that benefit appeared mostly in HR-disease. That said, lobular cancers are not chemotherapy insens...
What adjuvant chemotherapy regimen is most appropriate for a patient with local recurrence several years after surgery and ddAC-T for localized breast cancer?
I agree with @Dr. First Last. The CALOR study supports "physicians choice" chemotherapy in the setting of a local recurrence but unfortunately it doesn't guide specific chemotherapy regimens. My specific chemotherapy recommendations are often influenced by the disease free interval, histology, compl...
How do you approach systemic therapy for locoregional recurrence in a patient with triple negative breast cancer who has previously received anthracycline and taxane based chemotherapy?
The CALOR trial took a pragmatic approach and randomized patients to systemic therapy or not. A specific regimen wasn't specified. If the patient has a known BRCA mutation, I would extrapolate from the first line metastatic setting and use a single agent platinum. Outside of that unique situation, t...
What is your practice regarding axillary isolated recurrence after surgery when a patient received previous whole breast radiation?
I agree with @Dr. First Last on both counts. In the case of a deep, isolated, axillary recurrence, we start with NeoCT (based on the CALOR Trial data).Now, let's assume the patient has had prior comprehensive radiotherapy (breast and nodal), and now has smaller, but persistent isolated axillary dise...